Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.61 |
| ▸ | NPC1 | O15118 | 10/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23292571 | 0.81 | NOTUM (0.45) | RAB9ANPC1NOTUMMEN1KMT2A | |
| SCHEMBL23292595 | 0.81 | MAOA (0.47) | RAB9ANPC1NOTUMMEN1KMT2A | |
| SCHEMBL2159925 | 0.81 | MAPT (0.47) | RAB9ANPC1NOTUMMEN1KMT2A | |
| SCHEMBL2686660 | 0.81 | MAPT (0.47) | RAB9ANPC1NOTUMMEN1KMT2A | |
| SCHEMBL1787030 | 0.80 | RAB9A (0.53) | RAB9ANPC1NOTUMMEN1KMT2A | |
| SCHEMBL4093680 | 0.80 | RAB9A (0.46) | RAB9ANPC1NOTUMMEN1KMT2A | |
| SCHEMBL31215055 | 0.79 | KDM4E (0.46) | RAB9ANPC1NOTUMMEN1KMT2A | |
| SCHEMBL2159980 | 0.79 | PTGS2 (0.51) | RAB9ANPC1NOTUMMEN1KMT2A | |
| SCHEMBL474171 | 0.79 | NOTUM (0.61) | RAB9ANPC1NOTUMMEN1KMT2A | |
| SCHEMBL3358354 | 0.79 | RAB9A (0.56) | RAB9ANPC1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11165098-B2 | Substituted isoxazoles for lithium batteries | GOTION, INC. (US) | 2021-11-02 | — | — | US | claimed |
| CN-107636871-B | Substituted isoxazoles for lithium batteries | 国轩高科美国研究院 | 2021-02-09 | — | — | CN | claimed |
| CN-107628979-B | Method for synthesizing 2H-azacyclo acrylamide | 南京工业大学 | 2020-04-14 | — | — | CN | claimed |
| EP-2526098-B1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-07-11 | — | — | EP | claimed |
| US-20180138550-A1 | Substituted Isoxazoles For Lithium Batteries | GOTION INC (US) | 2018-05-17 | — | — | US | claimed |
| CN-107636871-A | Substitution isoxazole for lithium battery | 国轩高科美国研究院 | 2018-01-26 | — | — | CN | claimed |
| WO-2016166030-A1 | SUBSTITUTED ISOXAZOLES FOR LITHIUM BATTERIES | BASF SE (DE) | 2016-10-20 | — | — | WO | claimed |
| US-8470820-B2 | Nitrogen-containing heteroaryl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | claimed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | claimed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | claimed |
| US-7297168-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-11-20 | — | — | US | claimed |
| EP-1636220-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-09-15 | — | — | US | claimed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| JP-63188625-A | — | — | None | — | — | JP | disclosed |
| EP-4713306-A1 | NOVEL TRACER FOR THE IN VIVO DETECTION OF THE AGGREGATION OF ALPHA-SYNUCLEIN | Stichting Amsterdam UMC (NL) | 2026-03-25 | — | — | EP | disclosed |
| WO-2005074875-A2 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| JP-S63188625-A | NOVEL AMINOISOXAZOLE DERIVATIVE AND REMEDY FOR CEREBROVASCULAR DISORDER COMPRISING SAID DERIVATIVE AS ACTIVE INGREDIENT | MITSUI TOATSU CHEM INC | 1988-08-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | RAB9A 2182/4885NPC1 1425/4885NOTUM 2438/4885 |
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, CYB5R3 | RAB9A 4235/4885NPC1 4814/4885NOTUM 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.